CPRIT approves nine product-development awards, authorizes advanced payments and a competitive cost-adjustment RFA

Summary

The oversight committee approved nine product development awards after full review and due diligence, delegated contracting authority, authorized advanced payments consistent with the General Appropriations Act, and approved a proposed competitive cost-adjustment RFA to reallocate leftover funds to high-performing existing grantees.

The CPRIT oversight committee approved nine product development research awards after a competitive multi-stage review and delegated contract negotiation authority to the CEO and staff.

Chief product development officer Dr. Ken Smith reported that the program received a record 90 preliminary applications for the cycle; panels advanced 22 full applications to review, and the Program Integration Committee recommended nine awards after interviews and due diligence. The nine companies recommended covered a range of therapeutic and diagnostic efforts, including blood-based early detection of hepatocellular carcinoma (Curve Biosciences), a prior grantee’s T-cell therapy for metastatic pancreatic cancer (MyTeller Therapeutics/My Marker Therapeutics), a telomere-lengthening platform to extend CAR-T activity (Telos Biotech), a personal cancer vaccine program for head and neck cancer (Membrex/MediClips), a colorectal cancer-targeted small molecule (Barricade), a bispecific T-cell engager for CT83-expressing solid tumors (Ypsilon), an oral inhibitor for adrenocortical carcinoma (Orphanogen), a PARP/ALC1-targeting agent for HR-deficient tumors (Eisbach Bio/“EyesBack Bio”…

CPRIT approves nine product-development awards, authorizes advanced payments and a competitive cost-adjustment RFA

Summary

Subscribe to keep reading